Literature DB >> 17563854

Jaw osteonecrosis in patients treated with bisphosphonates: MDCT evaluation.

P Milillo1, A P Garribba, G Favia, G C Ettorre.   

Abstract

PURPOSE: This study was done to evaluate the use of multidetector computed tomography (MDCT) in the evaluation of jaw osteonecrosis, a recently described medical entity in patients receiving long-term intravenous or oral bisphosphonates, and to help radiologists recognise it to enable early diagnosis and appropriate management.
MATERIAL AND METHODS: Thirty-eight patients with a history of neoplasm (breast, prostate, multiple myeloma, pancreas) or osteoporosis and bisphosphonate use and recent oral surgery who presented with pain in the mouth and temporomandibular joints, soft tissue infections, altered taste and numbness were examined with MDCT.
RESULTS: In all patients, MDCT revealed the presence of structural bony alterations referable to osteonecrosis associated with orosinusal fistula in four of them and bony intraoral spicules in 25.
CONCLUSIONS: Jaw osteonecrosis is an established medical entity discovered in patients who have undergone treatment with bisphosphonates and dental extraction or other oral surgery. MDCT with multiplanar (MPR), volume rendering (VR) and three-dimensional (3D) reconstructions allows accurate assessment of affected bone structures, enabling early diagnosis and suitable treatment planning. Radiologists should be aware of the risk of osteonecrosis in patients treated with bisphosphonates and be able to distinguish it from other bone diseases (osteomyelitis and osteoradionecrosis) with which it enters the differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563854     DOI: 10.1007/s11547-007-0155-3

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   6.313


  18 in total

1.  Ten years of alendronate treatment for osteoporosis in postmenopausal women.

Authors:  Nina H Bjarnason
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

2.  Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

Authors:  Alessandro M Vannucchi; Giuseppe Ficarra; Elisabetta Antonioli; Alberto Bosi
Journal:  Br J Haematol       Date:  2005-03       Impact factor: 6.998

Review 3.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.

Authors:  G Ficarra; F Beninati; I Rubino; A Vannucchi; G Longo; P Tonelli; G Pini Prato
Journal:  J Clin Periodontol       Date:  2005-11       Impact factor: 8.728

5.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

Review 6.  Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?

Authors:  John W Hellstein; Cindy L Marek
Journal:  J Oral Maxillofac Surg       Date:  2005-05       Impact factor: 1.895

7.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

8.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

Authors:  M Sahni; H L Guenther; H Fleisch; P Collin; T J Martin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

10.  Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.

Authors:  Yu Z Bagger; László B Tankó; Peter Alexandersen; Pernille Ravn; Claus Christiansen
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

View more
  2 in total

1.  Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis.

Authors:  Kamile Leonardi Dutra; Letícia Fernanda Haas; Glaucia S Zimmermann; Gilberto Melo; Mariana Comparotto Minamisako; Carlos Flores-Mir; Márcio Corrêa
Journal:  Dentomaxillofac Radiol       Date:  2018-11-07       Impact factor: 2.419

Review 2.  Factors associated with osteonecrosis of the jaw among bisphosphonate users.

Authors:  Lisa M Hess; Joanne M Jeter; Marge Benham-Hutchins; David S Alberts
Journal:  Am J Med       Date:  2008-06       Impact factor: 4.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.